中国医药：涉1.39亿元诉讼案件进入二审阶段

Core Viewpoint - The company has initiated a lawsuit against Tibet Tiansheng Taifeng Pharmaceutical Co., Ltd. and Xu Panfeng due to a contract dispute arising from performance compensation, with the case now in the second instance stage [1] Group 1: Legal Proceedings - The lawsuit was filed in October 2024, and both the company and Tibet Tiansheng have appealed within the legal timeframe after the first-instance judgment [1] - The amount involved in the case is 139.4041 million yuan [1] - As of the announcement date, the second-instance hearing has not yet commenced, leading to uncertainty regarding the final outcome [1]